Both FLT3-ITD and FLT3 tyrosine kinase domain (FLT3-TKD) mutations activate constitutive ligand-independent FLT3 kinase activity and thereby STAT5 signaling, resulting in the proliferation and survival of AML cells [1,3]. This evidence concerns the gene FLT3 and acute myeloid leukemia.